Skip to main content

Using the Laser in Correcting Anemia in Hemodialysis Patients

Buy Article:

$43.00 plus tax (Refund Policy)

One of the main symptoms of terminal-stage chronic renal insufficiency is anemia. One of the best applicable methods correcting anemia is using recombinant human erythropoietin preparation. Using recombinant human erythropoietin in patients with terminal-stage chronic renal insufficiency in 90–95% of events had a positive effect, but 5–10% of patient had refraction to erythropoietin, which has spurred the search for new efficient methods correcting anemia. The purpose of the study was to determine the influence of the laser on erythropoiesis and blood acid–alkaline condition (pH) in patients with terminal-stage chronic renal insufficiency. In the course of the study, erythrocytes, hemoglobin, reticulocytes in blood, and blood acid–alkaline condition (pH) were determined. At the beginning of the treatment, all hematological parameters 5 and 15 days after marrow stimulation were defined. 15 days after marrow stimulation with laser, increasing amounts of erythrocytes, hemoglobin, and hematocrit were observed. The initial erythrocyte count was 2.22 ± 0.1 × 1012/L, hemoglobin 67.7 ± 3.2 g/L and hematocrit 18.2 ± 1.2%. During the laser treatment, erythrocyte count increased up to 2.9 ± 0.8 × 1012/L, hemoglobin up to 89.6 ± 2.9 g/L and hematocrit up to 28.2 ± 1.3% (p < 0005).
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: Syzganov Scientific Center of Surgery, Almaty, Kazakhstan.

Publication date: 2004-01-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more